STOCK TITAN
  1. Home
  2. News
  3. BICX

BioCorRx Inc - BICX STOCK NEWS

Welcome to our dedicated news page for BioCorRx (Ticker: BICX), a resource for investors and traders seeking the latest updates and insights on BioCorRx.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioCorRx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioCorRx's position in the market.

News
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
Rhea-AI Summary
BioCorRx Inc. (BICX) announces the granting of a new patent by the USPTO for the treatment of pain and neurological conditions. The patent focuses on a compound for treating pain, depression, and schizophrenia, potentially improving withdrawal symptoms for opioid use disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.66%
Tags
none
-
News
BioCorRx Reports Business Update for 2023
Rhea-AI Summary
BioCorRx Inc. provided a business update for the year ended December 31, 2023, highlighting positive Phase I clinical trial results for BICX104, an implantable naltrexone pellet for opioid use disorder. The company also secured an $11 million grant for developing BICX104 for methamphetamine use disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.91%
Tags
none
-
News
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
Rhea-AI Summary
BioCorRx Inc. announced that its subsidiary BioCorRx Pharmaceuticals Inc. has received an $11 million grant from NIDA to develop BICX104, a naltrexone implantable pellet for the treatment of methamphetamine use disorder. The grant aims to address the increasing prevalence of MUD and methamphetamine-related issues in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
News
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
Rhea-AI Summary
BioCorRx Inc. announced the appointment of Dr. Kate Beebe DeVarney, a renowned neuroscientist with 28 years of experience in the pharmaceutical industry, to its subsidiary BioCorRx Pharmaceuticals Inc.'s Board of Directors. Dr. DeVarney has a strong track record in developing and obtaining regulatory approval for treatments for people with substance use disorder. She will be instrumental in moving BICX104, an implantable naltrexone pellet for the treatment of opioid use disorder, through the regulatory pathway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.12%
Tags
management
-
News
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
Rhea-AI Summary
BioCorRx Inc. (OTCQB: BICX) appoints Louis Lucido as Interim President, effective immediately through January 31, 2024, and as President on February 1, 2024. Brady Granier resigns as President and CEO of BioCorRx Pharmaceuticals, effective January 31, 2024. Mr. Granier will continue to serve as a Member of the Company’s Board of Directors. Louis Lucido brings extensive business acumen and experience in corporate finance and capital markets, having founded and helped run a multi-billion-dollar asset management firm. The Company plans for a Nasdaq listing, and Mr. Lucido aims to accelerate growth, increase market awareness, and drive value for shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.89%
Tags
management
-
News
BioCorRx Reports Business Update for the Third Quarter of 2023
Rhea-AI Summary
BioCorRx Inc. (OTCQB: BICX) provided a business update for the three months ended September 30, 2023, highlighting positive safety and pharmacokinetic results for the Phase I clinical trial of BICX104, a treatment program for substance abuse. The company aims to address the opioid epidemic by offering enhanced relapse protection and managing expenses effectively. The quarterly report on Form 10-Q is available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18%
Tags
none
News
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.85%
Tags
none
-
News
BioCorRx Reports Business Update for the Second Quarter of 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.85%
Tags
none
-
News
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
Rhea-AI Summary
BioCorRx Inc. (OTCQB: BICX) has submitted a fast track application to the FDA for BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD). The fast track designation aims to expedite the development and review of new drugs intended to treat serious or life-threatening conditions, with the potential to fill unmet medical needs. The submission follows interim positive safety and pharmacokinetic results for the Phase I clinical trial, showing that BICX104 was generally well-tolerated and provided therapeutic levels of naltrexone for a mean of 84 days. The opioid overdose epidemic, causing an estimated 80,816 overdose deaths in 2021, is a significant public health crisis, and BioCorRx aims to make BICX104 available to patients and prescribers as soon as possible. The FDA typically responds to fast track designation requests within 60 days or less.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.82%
Tags
clinical trial
News
BioCorRx Provides Business Update for the First Quarter of 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.78%
Tags
none
Stock BICX logo
BioCorRx Inc

OTC:BICX

BICX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BICX Stock Data

12.96M
3.60M
60.87%
General Medical and Surgical Hospitals
Health Care and Social Assistance
Link
United States
Anaheim

About BICX

a company that changes lives biocorrx® is a leading edge healthcare solutions company focused on improving the lives of those struggling with alcohol and opioid addiction. designed to treat alcoholism and certain opioid addictions, the biocorrx® recovery program is used by a network of independently owned and operated treatment centers located throughout the united states. the program consists of a proprietary long-lasting implant of the fda approved medication, naltrexone, which is proven to substantially reduce cravings for drugs and alcohol. it's a high-quality, comprehensive and cost- effective recovery program built on a strong foundation of experience and practice, allowing for an improved quality of life for recovering addicts.